Controlled trial of ketorolac in tension-type headache.
Intramuscular ketorolac 60 mg, meperidine 50 mg plus promethazine 25 mg, and normal saline were compared in acute exacerbations of tension-type headache. Forty-one subjects (30 females and 11 males) were randomized into three groups and evaluated by the McGill Short-Form Pain Questionnaire before treatment, and 0.5, 1, 2, 3, 4, 5, and 6 hours after treatment. All three groups showed a significant treatment effect that persisted for the 6 hours of evaluation. Ketorolac treatment was significantly better than placebo at 0.5 and 1 hour by the Visual Analog Scale (VAS) and Pain Rating Index, and better than meperidine at 2 hours (by the VAS). Meperidine and placebo did not differ at any time point. Ketorolac is effective in short-term treatment of tension-type headache.
Harden
R N
RN
Rehabilitation Institute of Chicago, IL 60611, USA.
Rogers
D
D
Fink
K
K
Gracely
R H
RH
D000293:Adolescent; D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000627:therapeutic use*; D000704:Analysis of Variance; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D020910:Ketorolac; D008297:Male; D008614:Meperidine / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010147:Pain Measurement; D011398:Promethazine / Q000008:administration & dosage / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D018781:Tension-Type Headache / Q000188:drug therapy*; D014046:Tolmetin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D018712:Analgesics, Non-Narcotic; D008614:Meperidine; D014046:Tolmetin; D011398:Promethazine; D020910:Ketorolac